Ono Pharmaceutical Co. Ltd. has successfully completed its previously announced tender offer to acquire all outstanding shares of common stock of U.S. biopharmaceutical company Deciphera Pharmaceuticals Inc. for $25.60 per share (total amount of approximately $2.4 billion), through its wholly-owned subsidiary, Topaz Merger Sub Inc.   Following the completion of the tender offer, Merger Sub merged with and into Deciphera with Deciphera continuing as the surviving corporation and a wholly owned ...